Culture media capable of promoting differentiation of pluripotent stem cells (PSCs) into mesenchymal stem cells (MSCs) or supporting expansion of MSCs is provided. Methods of differentiation of PSCs into MSCs are provided. Methods of expanding MSCs without differentiation are also provided.

A non-degradable device for use in controlled feeding of mammalian cell cultures including by way of example cultures of stem cells such as induced pluripotent stem cells (iPSCs). Methods of making and using the device are also disclosed.

In order to induce aging while cutting the costs associated with adding cytokines at different aging stages, in a system for aging induction including a first culture chamber for perfusing, with a culture medium, a subject of aging-induction, the subject of aging-induction being derived from a living organism; a second culture chamber for perfusing, with a culture medium, a secretor that secretes a cytokine; and a control device for aging induction including a detection unit, a memory unit and a control unit, a protocol for aging induction defining a procedure of aging induction is stored, and in the control unit, an aging state of the subject of aging-induction is detected with a detection unit, and based on the protocol for aging induction, a flow rate at which the culture medium containing the cytokine secreted by the secretor is supplied to the subject of aging-induction is controlled according to the aging state of the subject of aging-induction.

The invention relates to a method for differentiating human pluripotent stem cells into fibroblasts, characterized in that the human pluripotent stem cells are cultured on an adherent system in the presence of a medium that is suitable for culturing fibroblasts and in the absence of feeder cells.

The present invention relates to a platelet lysate foam obtained from blood derivative (allogenic or autologous) which retains the biological properties of the platelet lysate and has optimal properties, in particular mechanical but also storage, which allow sale thereof and make handling thereof easier.

The present invention also relates to the use of a platelet lysate foam for therapeutic purposes, cell culture and cell therapy.

The present invention also relates to a process for getting a platelet lysate foam by a process of drying in a supercritical CO.sub.2 atmosphere.

Cells in a given population often display heterogeneity that may affect how each cell responds to a particular treatment or growth condition. The methods described herein allow determination of which cells from an initial population survive a treatment or condition, and how surviving cells evolve over time. For example, the methods described herein may be used to model drug resistance, response and/or adaptation in a cell population.

The present invention provides a chromosome-stabilizing agent for stem cells containing a β-nicotinamide mononucleotide or a pharmaceutically acceptable salt thereof, or a solvate thereof, as an active ingredient. The present invention also provides a culture method for stem cells, including culturing stem cells in a culture medium containing a β-nicotinamide mononucleotide or a pharmaceutically acceptable salt thereof, or a solvate thereof.

The invention provides a bioactive substance composition, a serum-free medium comprising the composition and the uses thereof. The bioactive substance composition is used for serum-free medium and/or composition and the preparation thereof; The serum-free medium and/or composition can be used for primary culture and secondary culture of cells and/or tissues. The cells are selected from any one or more of tendon and/or ligament derived cells, chondrocytes, meniscus stem cells, mesenchymal stem cells, skeleton stem cells, and muscle stem cells. The tissue is the musculoskeletal system tissue. The bioactive substance composition and/or serum-free medium and/or the composition can be used to prepare drugs for tissue and/or organ injury treatment; The tissue or organ injury is selected from the tissue or organ injury of the musculoskeletal system.

The method for producing a cell aggregate including glial progenitor cells according to the present invention comprises: (1) a step of subjecting pluripotent stem cells to suspension culture in an embryoid-body-forming culture medium containing one or more SMAD signaling inhibitors and one or more Wnt signaling activators in the absence of feeder cells for 5 days to 10 days, to form a cell aggregate; (2) a step of subjecting the cell aggregate obtained in (1) to suspension culture in an embryoid-body-forming culture medium containing retinoic acid; (3) a step of subjecting the cell aggregate obtained in (2) to suspension culture in an embryoid-body-forming culture medium or neuron-and-glia-proliferating culture medium containing retinoic acid and one or more SHH signaling activators; and (4) a step of subjecting the cell aggregate obtained in (3) to suspension culture in a neuron-and-glia-proliferating culture medium containing no retinoic acid and one or more SHH signaling activators.

Methods are described for preparing auditory progenitor cells from gingival mesenchymal cells, for uses such as restoring hearing in hearing impaired individuals. In one aspect, a method of treating hearing loss associated with loss of sensory neurons in a human subject is provided, the method comprising the steps of: a. obtaining a population of gingival mesenchymal stem cells (GMSCs); b. optionally expanding the population of GMSCs in vitro; c. encapsulating the population of GMSCs in an elastic three-dimensional scaffold; d. exposing the encapsulated population of GMSCs to a composition comprising one or more growth factors; e. allowing co a sufficient period for the population of GMSCs to differentiate towards auditory progenitor cells; f. optionally retrieving the auditory progenitor cells from the scaffold; and g. introducing the auditory progenitor cells into the inner ear of the subject.